Your browser doesn't support javascript.
loading
The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas.
Cleverley, Tesia L; Peddineni, Siri; Guarner, Jeannette; Cingolani, Francesca; Garcia, Pamela K; Koehler, Heather; Mocarski, Edward S; Kalman, Daniel.
Afiliación
  • Cleverley TL; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
  • Peddineni S; Immunology and Molecular Pathogenesis Graduate Program, Emory University School of Medicine, Atlanta, Georgia, United States of America.
  • Guarner J; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
  • Cingolani F; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
  • Garcia PK; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
  • Koehler H; Immunology and Molecular Pathogenesis Graduate Program, Emory University School of Medicine, Atlanta, Georgia, United States of America.
  • Mocarski ES; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
  • Kalman D; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
PLoS Pathog ; 19(5): e1011387, 2023 05.
Article en En | MEDLINE | ID: mdl-37200402

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperazinas / Pirimidinas Tipo de estudio: Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: PLoS Pathog Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperazinas / Pirimidinas Tipo de estudio: Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: PLoS Pathog Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos